Sendero Wealth Management LLC Has $3.99 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Sendero Wealth Management LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 35.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 46,413 shares of the company’s stock after purchasing an additional 12,142 shares during the quarter. Sendero Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $3,992,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Massachusetts Financial Services Co. MA boosted its holdings in Novo Nordisk A/S by 2.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 77,494 shares of the company’s stock worth $11,061,000 after purchasing an additional 1,860 shares during the last quarter. Pekin Hardy Strauss Inc. grew its holdings in shares of Novo Nordisk A/S by 20.1% in the second quarter. Pekin Hardy Strauss Inc. now owns 7,165 shares of the company’s stock valued at $1,023,000 after acquiring an additional 1,200 shares in the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S by 16.1% in the second quarter. Axxcess Wealth Management LLC now owns 27,715 shares of the company’s stock valued at $3,956,000 after acquiring an additional 3,834 shares in the last quarter. Financial & Tax Architects LLC lifted its holdings in Novo Nordisk A/S by 35.2% during the second quarter. Financial & Tax Architects LLC now owns 3,991 shares of the company’s stock worth $570,000 after acquiring an additional 1,039 shares during the period. Finally, Bradley Foster & Sargent Inc. CT boosted its position in Novo Nordisk A/S by 4.6% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 67,244 shares of the company’s stock worth $9,598,000 after purchasing an additional 2,977 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 2.2 %

NVO stock opened at $82.99 on Thursday. Novo Nordisk A/S has a twelve month low of $80.05 and a twelve month high of $148.15. The firm has a market capitalization of $372.42 billion, a PE ratio of 26.86, a PEG ratio of 0.92 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $99.26 and a two-hundred day simple moving average of $118.18.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.